Business Development

Business Model
Griffin Discoveries develops and commercializes a portfolio of GPCR drug candidates for the treatment of several inflammatory disorders. The development will be pursued to a point that clear proof of principle has been demonstrated in animal models and the candidate compounds will be ready for use in Phase I clinical studies. Subsequent development will be achieved either through out-licensing of the drug candidate or in collaboration with a partner from the pharmaceutical industry.

Cash flow and short-term value will be generated through GPCR service contracts and drug discovery collaborations with the pharmaceutical industry and biotech companies. Long term value is created by the progress of Griffin Discoveries’ in-house discovery programs.

  • SKE (Knowledge Exploitation Funding Programme, Amsterdam)
  • VU University Amsterdam

Investment Strategy
Griffin Discoveries is currently able to operate without third party investors. However, the progression of our in-house R&D programs will require third party investments on the long-term. It is foreseen that future investments will be made through collaborative R&D projects or as venture capital.